InfluenzaNCT07030075
Surveillance, Assessment and Detection of Influenza Associated Respiratory Infections in HIV Positive and Negative Individual in Lusaka, Zambia.
An observational study of Influenza and RSV, run by Centre for Infectious Disease Research in Zambia at 2 sites in Zambia.
Trial summary
Background and rationale:The World Health Organisation (WHO), estimates influenza global deaths at 290,000 to 650,000 annually. Although influenza is mostly associated with upper respiratory tract infections (URTIs), its role in lower respiratory tract infections (LRTIs) and the associated poor clinical outcomes have… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Influenza, RSV, COVID - 19
- How many people
- 594 participants
- Where
- 2 sitesZambia
- Study dates
- 20 May 2025to Jan 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Persons encountered at the facility entry points will be informed of the study through sensitization activities. Entry points will include the outpatient departments (OPD), emergency room, antiretroviral therapy (ART) clinics, chest clinics, and maternal and child health (MCH) clinics. All adults over the age of 18 years old presenting with flu-like symptoms will be screened for eligibility.
Who may be able to join
- age ≥18 years old
- presenting with flu-like symptoms or acute respiratory infection with ≥2 to 7 days history of cough and /or sore throat and fever, +/- sneezing, +/- congestion, +/- myalgia, +/- fatigue, +/- wheezing, shortness of breath)[55-57]
- willing to share their HIV status or be tested
- willing to share their COVID-19 vaccination status
- able and willing to give informed consent
- willing to provide a nasal/ nasopharyngeal sample for testing as part of standard of care
Show all 9Show fewer
- willing to provide exhaled breath aerosol samples i.e. wear a mask and provide a breath sample
- willing to fill a symptoms diary card for symptom tracking for 7 days
- agree to be followed-up and attend study visits up to two weeks after study entry
Who cannot join
- individuals who are unwilling to provide any reference standard samples such as the nasopharyngeal swabs
- those with symptoms for >7 days, or
- those unwilling or unable to provide informed consent
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Zambia2 sites, 2 recruiting
- Recruiting
Chawama 1st level Hospital
Lusaka, Lusaka Province, 10101
Seke Muzazu, +260968332433, seke.muzazu@cidrz.org
Seke Muzazu, MD
- Recruiting
Kanyama 1st Level Hospital
Lusaka, Lusaka Province, 10101
Seke Muzazu, MD, +260968332433, seke.muzazu@cidrz.org
Seke Muzazu, MD
About this study
Official title: Surveillance, Assessment and Detection of Influenza-Associated Respiratory Infections in HIV-Positive and HIV-Negative Individuals in Lusaka, Zambia
Background and rationale:The World Health Organisation (WHO), estimates influenza global deaths at 290,000 to 650,000 annually. Although influenza is mostly associated with upper respiratory tract infections (URTIs), its role in lower respiratory tract infections (LRTIs) and the associated poor clinical outcomes have been overlooked in sub-Saharan Africa. A study conducted in eight SSA countries estimated that 8.2% of cases and 2.8% of deaths from LRTIs were due to primary infection with influenza. Pneumonia and influenza-associated illness are responsible for 8.5% of respiratory deaths in Zambia. However, in routine practice, testing to distinguish between bacterial and viral etiology of RTIs is seldom done outside sentinel surveillance due to the high cost and lack of available testing options. This consequently underestimates viral RTIs in the population. It is particularly important to diagnose flu early on in vulnerable populations so that they receive timely and appropriate medical care. Although Zambia is a high HIV burden country with a prevalence of 11%, there is presently no study that has described the burden of influenza in the HIV positive population. This research study will address gaps in current scientific knowledge, providing key insights about the prevalence, circulating types, seasonality and associated clinical outcomes of influenza, RSV and SARS-CoV-2 infection in Zambia in the post COVID-19 era.
Objectives Primary To determine the prevalence of influenza (A and/or B) infections in a high HIV burden setting in Lusaka, Zambia over one or more influenza seasons.
Read more
Secondary
- To determine the prevalence of influenza co-infection with RSV and/or SARS-CoV-2
- To determine the clinical outcomes of influenza (A and/or B) infection among Zambian adults, with and without co-infection with RSV and COVID-19, by HIV and COVID-19 vaccination status.
- To evaluate the accuracy and yield of aerosol-based sampling for diagnosis of respiratory viruses (influenza, SARS-CoV-2, and RSV) compared to nasal/ nasopharyngeal swabs, for rapid diagnosis of infection among symptomatic individuals in Zambia.
- To evaluate the acceptability of exhaled breath aerosol (XBA) sampling for diagnosis and screening of respiratory infections of pandemic potential.
Study design and participants:
Primary objective and secondary objective 1:
Cross sectional surveillance study of individuals presenting with flu-like symptoms at two first level hospitals in Lusaka, Zambia. Recruitment of 594 participants will be done over the study period and participants will include both males and females presenting with 2-7 days of flu-like symptoms, able to provide informed consent, aged ≥18 years, with a known HIV status or willing to be tested, with a known COVID 19 vaccination status and available for symptom follow-up.
Secondary objective 2:
Prospective follow up of participants enrolled in aim 1 for 14 days will be done to document clinical symptom progression and outcomes. Appropriate care will be provided to all participants within routine care services.
Secondary objective 3 \& 4:
Mixed methods approach. All patients enrolled under aim 1 will be requested to provide in addition to the routine nasopharyngeal sample, an aerosol-based sample for diagnostic accuracy and yield evaluation. We will also conduct an investigator-administered questionnaire to ascertain end-user experience and preferences for either sampling method.
Location Zambia (Kanyama and Chawama sub-districts) Duration April 2025 to November 2026 (Participant enrolment duration)
- Conditions
- Influenza, RSV, COVID - 19
- Medical subject headings
- Influenza, Human, COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence
Proportion of participants with a positive test (Influenza, RSV or COVID) over the total number of study participants
Measured: 18months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2025
- Study start20 May 2025
- Primary completionDec 2026 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfluenzaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 594 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre for Infectious Disease Research in Zambia
- Sponsor type
- University, hospital or other
- Collaborators
- Heidelberg University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07030075
- Sponsor's protocol ID
- 5955-2024
- Status last verified
- Aug 2026
- First submitted
- 12 Jun 2025
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No